these results provide confirmatory evidence for the postulated role of aldophosphamide as an intermediate in cp metabolism and suggest , furthermore , that aldophosphamide itself is not active in vivo , requiring transformation to nsc-69945 via beta-elimination of acrolein to exert its antitumor effects .
C0025519
metabolism
C0221102
elimination